Medpace Holdings Inc
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medica… Read more
Market Cap & Net Worth: Medpace Holdings Inc (MEDP)
Medpace Holdings Inc (NASDAQ:MEDP) has a market capitalization of $12.87 Billion ($12.87 Billion) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #1632 globally and #1219 in its home market, demonstrating a -3.60% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Medpace Holdings Inc's stock price $453.64 by its total outstanding shares 28381283 (28.38 Million).
Medpace Holdings Inc Market Cap History: 2016 to 2026
Medpace Holdings Inc's market capitalization history from 2016 to 2026. Data shows growth from $1.02 Billion to $12.87 Billion (33.65% CAGR).
Index Memberships
Medpace Holdings Inc is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.46% | #37 of 976 |
|
NASDAQ Composite
IXIC
|
$33.26 Trillion | 0.03% | #221 of 3165 |
|
S&P Midcap 400
MID
|
$3.04 Trillion | 0.28% | #89 of 401 |
|
NASDAQ Biotechnology
NBI
|
$1.54 Trillion | 0.67% | #24 of 263 |
Weight: Medpace Holdings Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Medpace Holdings Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Medpace Holdings Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
6.30x
Medpace Holdings Inc's market cap is 6.30 times its annual revenue
0.68x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
35.33x
Medpace Holdings Inc's market cap is 35.33 times its annual earnings
359.02x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.02 Billion | $421.58 Million | $13.43 Million | 2.43x | 76.25x |
| 2017 | $1.03 Billion | $436.15 Million | $39.12 Million | 2.36x | 26.31x |
| 2018 | $1.50 Billion | $704.59 Million | $73.19 Million | 2.13x | 20.53x |
| 2019 | $2.39 Billion | $860.97 Million | $100.44 Million | 2.77x | 23.75x |
| 2020 | $3.95 Billion | $925.92 Million | $145.38 Million | 4.27x | 27.17x |
| 2021 | $6.18 Billion | $1.14 Billion | $181.85 Million | 5.41x | 33.97x |
| 2022 | $6.03 Billion | $1.46 Billion | $245.37 Million | 4.13x | 24.57x |
| 2023 | $8.70 Billion | $1.89 Billion | $282.81 Million | 4.61x | 30.76x |
| 2024 | $9.43 Billion | $2.11 Billion | $404.39 Million | 4.47x | 23.32x |
| 2025 | $15.94 Billion | $2.53 Billion | $451.12 Million | 6.30x | 35.33x |
Competitor Companies of MEDP by Market Capitalization
Companies near Medpace Holdings Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Medpace Holdings Inc by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #91 globally with a market cap of $176.18 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #154 globally with a market cap of $120.38 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #466 globally with a market cap of $46.34 Billion USD.
- Lonza Group Ltd (PINK:LZAGF): Ranked #512 globally with a market cap of $41.73 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #91 | Thermo Fisher Scientific Inc | NYSE:TMO | $176.18 Billion | $470.00 |
| #154 | Danaher Corporation | NYSE:DHR | $120.38 Billion | $191.39 |
| #466 | IDEXX Laboratories Inc | NASDAQ:IDXX | $46.34 Billion | $586.37 |
| #512 | Lonza Group Ltd | PINK:LZAGF | $41.73 Billion | $596.13 |
Medpace Holdings Inc Historical Marketcap From 2016 to 2026
Between 2016 and today, Medpace Holdings Inc's market cap moved from $1.02 Billion to $ 12.87 Billion, with a yearly change of 33.65%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $12.87 Billion | -19.23% |
| 2025 | $15.94 Billion | +69.05% |
| 2024 | $9.43 Billion | +8.38% |
| 2023 | $8.70 Billion | +44.31% |
| 2022 | $6.03 Billion | -2.40% |
| 2021 | $6.18 Billion | +56.35% |
| 2020 | $3.95 Billion | +65.60% |
| 2019 | $2.39 Billion | +58.81% |
| 2018 | $1.50 Billion | +45.97% |
| 2017 | $1.03 Billion | +0.53% |
| 2016 | $1.02 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Medpace Holdings Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $12.87 Billion USD |
| MoneyControl | $12.87 Billion USD |
| MarketWatch | $12.87 Billion USD |
| marketcap.company | $12.87 Billion USD |
| Reuters | $12.87 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.